Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 7: 963 - 966

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.07.019

Review

Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis

  • Hao-jun ZHUANG ,
  • Mei-liang GUO ,
  • Wan-wen LIU ,
  • Hui DENG
Expand
  • Department of Dermatology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China

Online published: 2021-08-03

Supported by

National Natural Science Foundation of China(81673054)

Fold

Abstract

Atopic dermatitis is a chronic inflammatory skin disease, which is mainly related to changes in Th2 type signaling pathways. Increased expression of interleukin-4 (IL-4) and IL-13 reduces filaggrin, which leads to skin barrier defects. The Janus kinase-singal transducer and activator of transcriprion (Jak-STAT) signaling pathway is closely related to the pathogenesis of atopic dermatitis. Inhibiting the Jak-STAT signaling pathway is a potential method to treat atopic dermatitis. Janus kinase (JAK) inhibitors can be divided into first-generation and second-generation JAK inhibitors in the selection of JAKs′ inhibition. By summarizing the efficacy and safety of the first-generation and second-generation JAK inhibitors in clinical trials, the clinical research progress of JAK inhibitors in the treatment of atopic dermatitis is clarified.

Key words： atopic dermatitis; Jak-STAT signaling pathway; JAK inhibitors

Cite this article

Hao-jun ZHUANG , Mei-liang GUO , Wan-wen LIU , Hui DENG . Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(7) : 963 -966 . DOI: 10.3969/j.issn.1674-8115.2021.07.019

References

1 Nutten S. Atopic dermatitis: global epidemiology and risk factors[J]. Ann Nutr Metab, 2015, 66(): 8-16.
2 Avena-Woods C. Overview of atopic dermatitis[J]. Am J Manag Care, 2017, 23(8): S115-S123.
3 Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications[J]. Allergy Asthma Proc, 2019, 40(2): 84-92.
4 Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects[J]. Drugs, 2017, 77(5): 521-546.
5 Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology[J]. Front Immunol, 2019, 10: 2847.
6 Gündüz ?. JAK/STAT pathway modulation: does it work in dermatology?[J]. Dermatol Ther, 2019, 32(3): e12903.
7 Weidinger S, Novak N. Atopic dermatitis[J]. Lancet, 2016, 387(10023): 1109-1122.
8 Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis[J]. J Dermatolog Treat, 2020, 31(1): 33-40.
9 王学川, 李霄, 梁承远. 基于JAK-STAT信号通路的药物研究进展[J]. 陕西科技大学学报, 2019, 37(6): 79-86.
10 Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases[J]. Nat Rev Drug Discov, 2017, 17(1): 78.
11 Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream[J]. J Allergy Clin Immunol, 2020, 145(2): 572-582.
12 Bertsias G. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors[J]. Mediterr J Rheumatol, 2020, 31(): 105-111.
13 Duggan S, Keam SJ. Upadacitinib: first approval[J]. Drugs, 2019, 79(16): 1819-1828.
14 Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology[J]. Indian Dermatol Online J, 2019, 10(5): 503-518.
15 Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase Ⅱa randomized trial[J]. Br J Dermatol, 2016, 175(5): 902-911.
16 Markham A. Baricitinib: first global approval[J]. Drugs, 2017, 77(6): 697-704.
17 Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study[J]. J Am Acad Dermatol, 2019, 80(4): 913-921.e9.
18 Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib[J]. Recent Results Cancer Res, 2018, 212: 119-132.
19 Dhillon S. Delgocitinib: first approval[J]. Drugs, 2020, 80(6): 609-615.
20 Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo[J]. Inflamm Res, 2015, 64(1): 41-51.
21 Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a janus kinase inhibitor, in japanese adult patients with moderate-to-severe atopic dermatitis: a phase Ⅱ, multicentre, randomized, vehicle-controlled clinical study[J]. Br J Dermatol, 2018, 178(2): 424-432.
22 Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)[J]. BMC Rheumatol, 2018, 2: 23.
23 Guttman-Yassky E, Tha?i D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145(3): 877-884.
24 Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib[J]. Am J Clin Dermatol, 2020, 21(6): 783-798.
25 Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial[J]. JAMA Dermatol, 2020, 156(8): 863-873.
Options
Outlines

/

〈 〉